An enquiry into antileishmanial activity and quantitative analysis of polyhydroxylated steroidal saponins from Solanum paniculatum L. leaves

Author(s)

Valerino-Diaz, Alexander B. ^[1] ; Zanatta, Ana C. ^[1] ; Gamiotea-Turro, Daylin ^[1] ; Bolela Bovo Candido, Ana Carolina ^[2] ; Magalhaes, Lizandra Guidi ^[2] ; Vilegas, Wagner ^[3] ; dos Santos, Lourdes Campaner ^[1]

Affiliation

^[1] Sao Paulo State Univ, UNESP, Inst Chem, Rua Prof Francisco Degni 55, BR-14800060 Araraquara, SP - Brazil

^[2] Univ Franca, Ctr Res Sci & Technol, Res Grp Nat Prod, Av Dr Armando Salles Oliveira 201, BR-14404600 Franca, SP - Brazil

^[3] Sao Paulo State Univ, UNESP, Inst Biosci, Praia Infante Dom Henrique S-N, BR-11330900 Sao Vicente, SP - Brazil

• Document type: Journal article
• Source: Journal of Pharmaceutical and Biomedical Analysis; v. 191, NOV 30 2020.
• Web of Science Citations: 0

Abstract

Solanum paniculatum L. is species whose fruits are widely consumed in Brazil as a tonic beverage with higher content of steroidal saponins. In this work, we developed an analytical method for the quantification of the eight saponins present in the 70 % ethanol extract from the leaves using ultra-high-performance liquid chromatography coupled to mass spectrometry (UHPLC-MS). Besides, the eight spirostanic saponins were screened for in vitro antileishmanial activity against promastigote and amastigote forms of Leishmania (L.) amazonensis. Substances 1, 2 and 3 were found to be the most active compounds, with inhibitory concentration (IC50) values of 8.51 +/- 4.38, 10.75 +/- 6.85 and 10.45 +/- 4.21 mu M, respectively, against promastigote forms and effective concentration (EC50) values of >25, 17.73 +/- 0.99 and 19.57 +/- 0.84 mu M, respectively, against amastigote forms. The cytotoxic test with compounds 1-3 evidenced low toxicity in murine macrophage cells, with values above 50 mu M at concentration lower than 25 mu M. These findings show that saponins 1-3 should be evaluated in further studies for the treatment of cutaneous leishmaniasis. (C) 2020 Elsevier B.V. All rights reserved. (AU)

• FAPESP's process: 09/52237-9 - Standardized herbal medicines for the treatment of chronic diseases
• Grantee: Wagner Vilegas
• Support Opportunities: BIOTA-FAPESP Program - Thematic Grants
• FAPESP's process: 16/21044-4 - Standardization of phytomedicines for the treatment of chronic diseases
• Grantee: Ana Caroline Zanatta Silva
• Support Opportunities: Scholarships in Brazil - Doctorate